中新社北京3月24日电(记者 夏宾)阿斯利康全球首席执行官(CEO)苏博科(Pascal Soriot)24日在北京接受中新社记者专访时表示，阿斯利康进入中国已逾三十年，对中国市场的持续深耕和投资充满期待。苏博科强调，阿斯利康致力于与本土企业合作，将中国的创新医药产品推向世界，同时也将全球的先进技术和产品引入中国，实现互利共赢。
苏博科指出，中国生物技术公司正逐渐在全球医药创新领域展现出巨大潜力，他们不仅能为中国的健康事业做出贡献，也能为全球患者带来新的治疗方案。他进一步表示，阿斯利康将继续加大在中国的研发和生产投入，与中国本土企业共同探索创新的商业模式和合作方式，推动中国乃至全球的医疗健康产业发展。
苏博科还提到，阿斯利康将利用其全球网络和资源，帮助中国生物技术公司实现国际化发展，同时通过引进国际先进的技术和产品，加速中国医药市场的创新进程。
英文标题：AstraZeneca CEO: China’s Biotech Firms Have Significant Potential for Global Healthcare Innovation
英文关键词：AstraZeneca, Biotechnology, Global Collaboration
英文新闻内容：
BEIJING, March 24 (Xinhua) — AstraZeneca Chief Executive Officer Pascal Soriot said in an exclusive interview with Xinhua in Beijing on Thursday that the company has been in China for more than 30 years and is eager to continue investing in the market. Soriot stressed that AstraZeneca is committed to working with local companies to bring innovative pharmaceutical products from China to the world and introduce advanced technologies and products from around the globe to China, achieving mutual benefit and win-win results.
Soriot pointed out that Chinese biotech firms are gradually demonstrating significant potential in the global healthcare innovation landscape. They not only contribute to China’s healthcare but also offer new treatment options to patients worldwide. He further stated that AstraZeneca will continue to increase its investment in research and development and production in China, exploring innovative business models and cooperation with local companies to drive the development of the healthcare industry in China and around the world.
Soriot also mentioned that AstraZeneca will leverage its global network and resources to help Chinese biotech firms achieve international development, and through the introduction of international advanced technologies and products, accelerate the process of innovation in the Chinese pharmaceutical market.
【来源】http://www.chinanews.com/cj/2024/03-25/10186125.shtml
Views: 1